HM 21001
Alternative Names: HM-21001Latest Information Update: 15 Jul 2021
At a glance
- Originator Ajou University School of Medicine
- Developer Hanmi Pharmaceutical
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 15 Jul 2021 Discontinued - Preclinical for Glioblastoma in South Korea (Parenteral) (Hanmi Pharmaceutical pipeline, July 2021)
- 24 Mar 2021 Preclinical development in Glioblastoma is still ongoing in South Korea (Parenteral) (Hanmi Pharmaceutical's pipeline, March 2021)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Glioblastoma in South Korea (Parenteral)